Date published: 2025-10-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

ABT1 Inhibitors

ABT1 inhibitors encompass a variety of chemical compounds that chiefly attenuate the functional activity of ABT1 through the intricate regulation of signaling cascades that converge upon ABT1. The inhibition of PI3K by Wortmannin and LY294002, for instance, precludes the phosphorylation of AKT, a pivotal kinase in the PI3K/AKT/mTOR axis, thereby indirectly thwarting the activation of ABT1. Similarly, Everolimus and Rapamycin exert their inhibitory effect by binding to FKBP12 and subsequently hampering mTOR, a kinase that is quintessential for ABT1's activation via phosphorylation. The suppression of AKT phosphorylation is also the mechanism of action for Triciribine, which specifically targets AKT, further impeding ABT1 activation. Dasatinib and PP2 disrupt ABT1 function by inhibiting Src family kinases, which play a role in various signaling pathways, including those that regulate ABT1. Moreover, ABT1 activity is indirectly modulated by inhibitors that target the MAPK signaling pathways. PD98059 and U0126, as specific inhibitors of MEK1/2, along with SB203580, which targets p38 MAPK, and SP600125, an antagonist of JNK, collectively contribute to the fine-tuning of ABT1's role in cell signaling. These inhibitors collectively diminish the cross-talk between the MAPK pathway and the pathways that ABT1 is a part of, leading to a decrease in ABT1's functional engagement. BKM120, with its broad spectrum inhibition of PI3K isoforms, amplifies the blockade of ABT1 activation.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin forms a complex with FKBP12 that binds to and inhibits mTOR, a kinase important for ABT1 signaling through the PI3K/AKT/mTOR pathway. Inhibition of mTOR leads to a decrease in ABT1 phosphorylation and activation.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is a potent and irreversible inhibitor of PI3K, which is upstream of ABT1 activation. By inhibiting PI3K, Wortmannin prevents the phosphorylation and activation of ABT1.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY294002 is another chemical inhibitor of PI3K, leading to reduced phosphorylation and activation of downstream targets including ABT1.

Triciribine

35943-35-2sc-200661
sc-200661A
1 mg
5 mg
$102.00
$138.00
14
(1)

Triciribine specifically inhibits the phosphorylation of AKT, which is necessary for the full activation of ABT1 in the PI3K/AKT pathway.

U-0126

109511-58-2sc-222395
sc-222395A
1 mg
5 mg
$63.00
$241.00
136
(2)

U0126 is a MEK inhibitor that, similar to PD98059, can indirectly decrease ABT1 activity by affecting the ERK signaling pathway.

SB 203580

152121-47-6sc-3533
sc-3533A
1 mg
5 mg
$88.00
$342.00
284
(5)

SB203580 is a p38 MAPK inhibitor, which can alter ABT1 function by affecting the stress-activated MAPK pathway that interacts with ABT1 signaling.

SP600125

129-56-6sc-200635
sc-200635A
10 mg
50 mg
$40.00
$150.00
257
(3)

SP600125 is an inhibitor of JNK, which modulates the activity of transcription factors that can influence ABT1 signaling pathways.

PP 2

172889-27-9sc-202769
sc-202769A
1 mg
5 mg
$92.00
$223.00
30
(1)

PP2 is an Src family kinase inhibitor which impedes the Src-mediated activation of multiple signaling pathways, including those that regulate ABT1 activity.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$47.00
$145.00
51
(1)

Dasatinib is a multikinase inhibitor that targets Src kinases and consequently decreases the activation of downstream pathways that regulate ABT1 activity.

BKM120

944396-07-0sc-364437
sc-364437A
sc-364437B
sc-364437C
5 mg
10 mg
25 mg
50 mg
$173.00
$230.00
$275.00
$332.00
9
(0)

BKM120 is a pan-PI3K inhibitor that, by broadly inhibiting PI3K isoforms, reduces the activation of ABT1 involved in PI3K signaling.